Have a feature idea you'd love to see implemented?
Let us know!
NKTR Nektar Therapeutics
Price (delayed)
$1.01
Market cap
$186.3M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.84
Enterprise value
$264.46M
Nektar Therapeutics is a biopharmaceutical company with a robust, wholly owned R&D pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines.
Highlights
Nektar Therapeutics's EPS has increased by 46% YoY and by 7% QoQ
The net income has grown by 43% year-on-year and by 5% since the previous quarter
Nektar Therapeutics's equity has shrunk by 69% YoY and by 39% QoQ
Nektar Therapeutics's quick ratio has decreased by 50% YoY and by 24% from the previous quarter
Key stats
What are the main financial stats of NKTR
Market
Valuations
Earnings
Shares outstanding
184.46M
Market cap
$186.3M
Enterprise value
$264.46M
Price to earnings (P/E)
N/A
Price to book (P/B)
3.8
Price to sales (P/S)
2.27
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.84
Revenue
$93.14M
EBIT
-$143.48M
EBITDA
-$137.77M
Free cash flow
-$177.82M
Per share
Balance sheet
Liquidity
EPS
-$0.84
Free cash flow per share
-$0.85
Book value per share
$0.27
Revenue per share
$0.45
TBVPS
$1.47
Total assets
$307.97M
Total liabilities
$259.08M
Debt
$108.26M
Equity
$48.88M
Working capital
$218.9M
Debt to equity
2.21
Current ratio
4.24
Quick ratio
3.62
Net debt/EBITDA
-0.57
Margins
Efficiency
Dividend
EBITDA margin
-147.9%
Gross margin
67.8%
Net margin
-180.7%
Operating margin
-164.3%
Return on assets
-46.6%
Return on equity
-174.3%
Return on invested capital
-37.6%
Return on capital employed
-59.7%
Return on sales
-154.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
NKTR stock price
How has the Nektar Therapeutics stock price performed over time
Intraday
1%
1 week
-13.68%
1 month
-27.34%
1 year
114.89%
YTD
78.76%
QTD
-22.31%
Financial performance
How have Nektar Therapeutics's revenue and profit performed over time
Revenue
$93.14M
Gross profit
$63.15M
Operating income
-$153.06M
Net income
-$168.3M
Gross margin
67.8%
Net margin
-180.7%
The operating margin has grown by 49% YoY and by 6% from the previous quarter
The operating income is up by 46% year-on-year and by 6% since the previous quarter
The net margin has increased by 46% YoY and by 4.9% QoQ
The net income has grown by 43% year-on-year and by 5% since the previous quarter
Growth
What is Nektar Therapeutics's growth rate over time
Valuation
What is Nektar Therapeutics stock price valuation
P/E
N/A
P/B
3.8
P/S
2.27
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.84
Nektar Therapeutics's EPS has increased by 46% YoY and by 7% QoQ
Nektar Therapeutics's equity has shrunk by 69% YoY and by 39% QoQ
The P/B is 65% above the 5-year quarterly average of 2.3 and 52% above the last 4 quarters average of 2.5
The stock's P/S is 84% less than its 5-year quarterly average of 13.8 but 3.2% more than its last 4 quarters average of 2.2
The revenue has grown by 6% YoY
Efficiency
How efficient is Nektar Therapeutics business performance
Nektar Therapeutics's return on sales has increased by 49% YoY and by 6% QoQ
Nektar Therapeutics's ROE has decreased by 43% YoY and by 22% from the previous quarter
The return on invested capital has grown by 25% year-on-year but it has declined by 2.2% since the previous quarter
NKTR's ROA is up by 12% YoY but it is down by 4% from the previous quarter
Dividends
What is NKTR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for NKTR.
Financial health
How did Nektar Therapeutics financials performed over time
Nektar Therapeutics's total assets is 19% more than its total liabilities
Nektar Therapeutics's quick ratio has decreased by 50% YoY and by 24% from the previous quarter
The company's current ratio fell by 45% YoY and by 18% QoQ
The debt is 121% higher than the equity
The debt to equity has soared by 191% YoY and by 57% QoQ
Nektar Therapeutics's equity has shrunk by 69% YoY and by 39% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.